Abstract
S-1108, a new oral cephem antibiotic, was evaluated in an open trial on 8 patients with respiratory infections, the dose being 100-150mg t. i. d. There were 7 cases of lower airway infections and one case of pneumonia.
Clinical effects were “good” in 6 and “fair” in 1 case, and one patient was lostto follow up.
With regard to bacteriological effect, one strain of Haemophilus influenzae was eradicated, and one strain of Streptococcus pneumoniae persisted.
No adverse effects were observed. Laboratory findings revealed a slight elevation of creatine phosphokinase in one case.
In conclusion, S-1108 is effective in the treatment of respiratory infections, and no serious toxicity was observed.
